Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $1.21 and traded as high as $1.2990. Sonoma Pharmaceuticals shares last traded at $1.24, with a volume of 324,217 shares changing hands.
Analyst Ratings Changes
Separately, Weiss Ratings downgraded shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Sonoma Pharmaceuticals currently has a consensus rating of “Sell”.
Check Out Our Latest Report on Sonoma Pharmaceuticals
Sonoma Pharmaceuticals Price Performance
The company has a market capitalization of $5.94 million, a PE ratio of -1.36 and a beta of 1.31. The company has a 50-day moving average of $1.21 and a two-hundred day moving average of $1.64.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.19. The business had revenue of $7.17 million during the quarter, compared to analysts’ expectations of $5.29 million. Sonoma Pharmaceuticals had a negative return on equity of 5.44% and a negative net margin of 7.65%.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment. The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions. Products marketed under the company’s brands have included Dermacyn, for wound and skin care, and Ocucyn, for ophthalmic care, along with veterinary products and other prescription and over-the-counter formulations.
Featured Stories
- Five stocks we like better than Sonoma Pharmaceuticals
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
